Drugs / Flu Pandemic mRNA
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06382311 | Apr 2024 → Jan 2026 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Flu Pandemic mRNA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06382311 ↗ |
| Modality | Messenger RNA (mRNA) | “mRNA-based investigational pandemic H5 influenza vaccine candidate” NCT06382311 ↗ |
| Route | Intramuscular | “2 doses of study intervention are administered to participants intramuscularly.” NCT06382311 ↗ |